Early

Advanced

 

 

UP

Down

UP

Down

 

 

N

MFC

N

MFC

N

MFC

N

MFC

Age(Years)

0-40

02

1.43

09

2.94

04

5.13

13

2.15

 

41-60

05

2.27

23

2.22

19

3.99

33

2.12

 

>60

00

-

03

2.83

01

1.44

06

2.68

Menopausal Status

PreM

03

1.63

13

2.30

09

6.27

22

2.12

 

PeriM

01

2.06

02

3.66*

06

2.29

10

2.20

 

PostM

03

2.42

20

2.42*

09

3.07

20

2.24

Nodal Status

N0

05

2.27

33ñ

2.35

06

3.24

09ñ

2.39

 

N+

02

1.43

02ñ

4.62

18

4.35

43ñ

2.14

Histologic Type

IDC

06

2.03

29

2.49

21

3.93

45

2.05^

 

ILC

01

2.06

01

4.01

00

-

02

9.61^

 

Others

00

-

05

1.95

03

5.08

05

2.98

Histologic Grade

I

01

2.31

10δ

2.20

02

1.26

05 δ

1.70

 

II+III

06

1.98

25 δ

2.51

22

4.33

47 δ

2.25

Stromal Invasiveness

Absent

00

-

00

-

00

-

02

5.71

 

Present

07

2.03

35

2.42

24

4.08

50

2.13

 

+

04

2.30

17

2.59

10

3.14∞

32

2.15

 

++

01

1.43

14

2.60é

11

3.12€

16

1.92ô

 

+++

02

1.79

04

1.58é

03

10.6∞€

02

7.24ô

*p=0.002, ñp=0.00001; ^p=0.036; δp=0.040; ∞p=0.009; €p=0.02; ép=0.047; ôp=0.03

Table 2: Correlation of TGF-β1 gene with the clinical and pathological prognosticators.